<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJRA</journal-id><journal-title-group><journal-title>Open Journal of Rheumatology and Autoimmune Diseases</journal-title></journal-title-group><issn pub-type="epub">2163-9914</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojra.2022.122007</article-id><article-id pub-id-type="publisher-id">OJRA-116709</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Asymptomatic Cardiac Manifestations in Rheumatoid Arthritis in Conakry (Guinea)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aly</surname><given-names>Badra Kamissoko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ibrahima</surname><given-names>Sory Barry</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Marina</surname><given-names>Sanda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cletus</surname><given-names>Dieuval Houngbegnon</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Lamine Diallo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdoulaye</surname><given-names>Barry</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Dadhi Baldé</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Owonayo</surname><given-names>Oniankitan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Cardiology, Ignace Deen National Hospital, Conakry, Guinea</addr-line></aff><aff id="aff3"><addr-line>Department of Rheumatology, Sylvanus Olympio University Hospital, Lome, Togo</addr-line></aff><aff id="aff1"><addr-line>Department of Rheumatology, Ignace Deen National Hospital, Conakry, Guinea</addr-line></aff><pub-date pub-type="epub"><day>22</day><month>04</month><year>2022</year></pub-date><volume>12</volume><issue>02</issue><fpage>57</fpage><lpage>64</lpage><history><date date-type="received"><day>27,</day>	<month>January</month>	<year>2022</year></date><date date-type="rev-recd"><day>19,</day>	<month>April</month>	<year>2022</year>	</date><date date-type="accepted"><day>22,</day>	<month>April</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Introduction:</b>
   Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease. It is a systemic disease with extra-articular manifestations that can be life-threatening. In sub-Saharan Africa, there is little published information on cardiovascular manifestations in RA. <b>Objective:</b> T
  he 
  o
  bjective is to
   determine the asymptomatic cardiac manifestations during rheumatoid arthritis in Conakry. <b>Patients and Methods:</b> This was a cross-
  sectional study lasting 6 months from January
   
  1, 2020 to June
   
  30, 2020 in the rheumatology and cardiology departments of the Ignace Deen National Hospital. Patients with RA diagnosed according to the 2010 ACR/EULAR criteria, asymptomatic at the cardiovascular level, which had an ECG and echocardiography, were included in the study. Left ventricular diastolic dysfunction was considered in any patient
   
  with an E/A ratio
   
  &lt;
   
  1, an E/E’ ratio &gt;
   
  10, and an LVEF =
   
  50%, assessed by the Simpson biplane method and classified according to Redfield. Epidemiological, clinical and paraclinical data were analyzed using SPSS statistics 21.0 software. <b>Results:</b> Seventeen cases of rheumatoid arthritis (5.9%) were collected. There was a predominance of women with 14 cases (82.4%). The mean age of patients was 48.2 &#177; 11.9 years. The average duration of RA was 7.2 &#177; 4.2 years. Cardiovascular risk factors were dominated by overweight and obesity (58.8%) and sedentary lifestyle (35.3%). RA was predominantly high activity (DAS 28 ≥ 5.1) in 82.4% of patients. Anti-CCP antibodies were positive in 76.9% of cases. Fourteen patients (82.4%) had abnormal cardiac results. The electrocardiogram showed left atrial hypertrophy in 29.4% of cases, left ventricular hypertrophy (11.8%) and ventricular extrasystole (11.8%). The cardiac Doppler scan showed diastolic dysfunction of the left ventricle (47.1%) and moderate pericardial effusion in 11.8% of cases. <b>Conclusion:</b> The study found asymptomatic cardiac manifestations of rheumatoid arthritis. They were dominated by ventricular hypertrophy on electrocardiogram and left ventricular diastolic dysfunction on cardiac Doppler ultrasound. Systematic examination of patients with RA is necessary to detect them early and avoid complications.
 
</p></abstract><kwd-group><kwd>Rheumatoid Arthritis</kwd><kwd> Asymptomatic Manifestations</kwd><kwd> Electrocardiography</kwd><kwd> Sub-Saharan Africa</kwd><kwd> Guinea</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease affecting approximately 0.5% - 1% of the world’s population [<xref ref-type="bibr" rid="scirp.116709-ref1">1</xref>]. The overall prevalence in sub-Saharan Africa can be estimated at 0.3% [<xref ref-type="bibr" rid="scirp.116709-ref2">2</xref>]. It is a systemic disease with numerous extra-articular manifestations [<xref ref-type="bibr" rid="scirp.116709-ref3">3</xref>], some of which may be life-threatening, with cardiovascular involvement being the most common [<xref ref-type="bibr" rid="scirp.116709-ref4">4</xref>]. The cardiovascular risk of RA is now well documented and represents the primary excess mortality factor in this disease [<xref ref-type="bibr" rid="scirp.116709-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref6">6</xref>]. The cardiovascular risk in RA is mainly related to the chronic inflammatory state which leads to numerous metabolic changes [<xref ref-type="bibr" rid="scirp.116709-ref7">7</xref>]. Asymptomatic cardiac manifestations are common in RA, but are not routinely investigated. Specific cardiac involvement in RA is often asymptomatic and discovered by ultrasound or autopsy [<xref ref-type="bibr" rid="scirp.116709-ref8">8</xref>]. In Africa, there are very few publications on cardiovascular manifestations during rheumatoid arthritis. In Senegal, in 2011, Ndongo S et al. found 36.5% of asymptomatic patients with at least one abnormality on ECG or electrocardiography [<xref ref-type="bibr" rid="scirp.116709-ref4">4</xref>]. In 2016, another study found that 16.9% of patients had a cardiovascular risk factor (CVRF) and many abnormalities were found on cardiac Doppler ultrasound in asymptomatic RA patients [<xref ref-type="bibr" rid="scirp.116709-ref9">9</xref>]. In Algeria, in 2020, the study of cardiovascular risk (CVR) in RA recommends a systematic assessment of CVR in patients in routine practice and the management of classical CVR [<xref ref-type="bibr" rid="scirp.116709-ref10">10</xref>]. According to Meryem M et al., the use of corticosteroids in the management of RA is responsible for cardiovascular disease due to the accumulation of risk factors [<xref ref-type="bibr" rid="scirp.116709-ref11">11</xref>]. The objective of this study was to describe asymptomatic cardiac manifestations during rheumatoid arthritis in Conakry.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>It was a cross-sectional study lasting 6 months from January 1, 2020 to June 30, 2020. It was conducted in the rheumatology and cardiology departments of the Ignace Deen National Hospital. All patients diagnosed with rheumatoid arthritis according to the ACR EULAR 2010 criteria [<xref ref-type="bibr" rid="scirp.116709-ref12">12</xref>] who were asymptomatic at the cardiovascular level were included. It was comprehensive recruitment. Each patient was required to have an ECG and echocardiography. For each patient, clinical and paraclinical features of rheumatoid arthritis were sought after rheumatologic examination. The devices used for the detection of cardiac manifestations were an electrocardiogram and an echo-Doppler allowing examination in time-motion (TM), two-dimensional, continuous, pulsed, color and tissue Doppler modes. The cardiac Doppler was performed and interpreted by the same cardiologist. Diastolic dysfunction was defined as: an E/A ratio less than 1, an E/E’ ratio greater than 10, measured on the lateral wall, and an LVEF = 50% evaluated by the Simpson biplane method. According to the Redfield classification, dysfunction was normal (0.75 &lt; E/A &lt; 1.5 and E/Ea &lt; 10; DT &gt; 140 ms), moderate (0.75 &lt; E/A &lt; 1.5 and E/Ea &gt; 10; DT &gt; 140 ms), moderate (E/A = 0.75 and E/Ea &lt; 10) or severe (severe E/A &gt; 1.5 and E/Ea &gt; 10; DT &lt; 140 ms).</p><p>Patients not included in the study were:</p><p>- With a known heart condition;</p><p>- With irregularly monitored high blood pressure (HBP);</p><p>- With symptoms suggestive of cardiovascular disease;</p><p>- With a cardiology treatment;</p><p>- Who did not give their consent.</p><p>The data were collected after careful questioning followed by clinical and paraclinical rheumatologic and cardiologic examinations. Those data were:</p><p>- Quantitative: age, duration of RA progression, Disease Activity Score 28 (DAS 28) which assesses the activity of rheumatoid arthritis in 28 joints [<xref ref-type="bibr" rid="scirp.116709-ref13">13</xref>]. RA is considered to be in remission if DAS 28 ≤ 2.6; mildly active if 2.6 &lt; DAS 28 ≤ 3.2; moderately active if 3.2 &lt; DAS 28 ≤ 5.1 and very active if DAS 28 &gt; 5.1. Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factors (RF), anti-CCP antibodies, morning roll, number of painful joints, number of swollen joints, number of awakenings during the night, Visual Analogue Scale (VAS) which assesses the intensity of the patient’s pain on a scale from 0 (no pain) to 10 (unbearable pain).</p><p>- Qualitative: gender, cardiovascular risk factors, electrocardiogram, cardiac echo-Doppler.</p><p>Data analysis was done using SPSS statistics 21.0. Categorical variables were expressed as numbers and percentages. The mean and standard deviation were calculated for quantitative data.</p></sec><sec id="s3"><title>3. Results</title><p>Seventeen cases of rheumatoid arthritis were collected for a prevalence of 5.9%. Fourteen patients (82.4%) were predominantly female, with a sex ratio rate (M/F) of 0.21. The mean age of the patients was 48.2 &#177; 11.9 years with extremes of 25 and 64 years. The mean duration of RA was 7.2 &#177; 4.2 years. A family history of chronic inflammatory rheumatism (CIR) was found in 23.5% of patients (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>In the study the main cardiovascular risk factors were overweight and obesity (58.8%), physical inactivity (52.9%) and dyslipidaemia (23.5%) (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>On rheumatologic examination, the average number of painful joints was 7.8 and an average of 2.5 joints was swollen. The pain caused an average of 1.2 night</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Socio-demographic characteristics of patients with rheumatoid arthritis who were cardiovascular asymptomatic</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >No.</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Women</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >82.4</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >17.6</td></tr><tr><td align="center" valign="middle" >Age</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >25 - 34 years</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11.8</td></tr><tr><td align="center" valign="middle" >35 - 44 years</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >29.4</td></tr><tr><td align="center" valign="middle" >45 - 64 years</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >23.5</td></tr><tr><td align="center" valign="middle" >Over 65 years</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >35.3</td></tr><tr><td align="center" valign="middle" >Family history of CIR</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >23.5</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >76.5</td></tr></tbody></table></table-wrap><p>Average age: 48.2 &#177; 11.9 years; Average duration of RA evolution: 7.2 years &#177; 4.2 years.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to cardiovascular risk factors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >No.</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Overweight/obesity</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >58.8</td></tr><tr><td align="center" valign="middle" >Sedentary lifestyle</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >52.9</td></tr><tr><td align="center" valign="middle" >Dyslipidemia</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >23.5</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >17.7</td></tr><tr><td align="center" valign="middle" >Smoking</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >5.9</td></tr></tbody></table></table-wrap><p>awakenings. Six patients had morning stiffness duration of less than 15min. RA was highly active (DAS 28 ≥ 5.1) in 82.4% of patients. Biological inflammatory syndrome was present with accelerated SV in 82.4% of cases and positive CRP in 80% of cases. Immunologically, rheumatoid factors were positive in 86.7% of cases and anti-CCP antibodies were positive in 76.9%. Abnormal cardiac findings were observed in 14 patients (82.4%) (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>The electrocardiogram showed left atrial hypertrophy in 29.4%, ventricular extrasystole in 11.8%, left ventricular hypertrophy in 11.8% and QRS abnormalities in 5.9% (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>Cardiac Doppler abnormalities were dominated by left ventricular diastolic dysfunction (29.4%) which was mild for 5 patients (29.4%), moderate for 2 patients (11.8%) and very active for 1 (5.9%); and moderate pericardial effusion (11.8%) (<xref ref-type="table" rid="table5">Table 5</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>The study focused on cardiovascularly asymptomatic rheumatoid arthritis (RA) patients. This was a preliminary study, the main difficulties of which were the</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of patients by clinical and biological characteristics of rheumatoid arthritis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >No. (%)</th><th align="center" valign="middle" >M &#177; SD</th></tr></thead><tr><td align="center" valign="middle" >Number of painful joints</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7.8 &#177; 3.9</td></tr><tr><td align="center" valign="middle" >Number of swollen joints</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.5 &#177; 1.5</td></tr><tr><td align="center" valign="middle" >Night-time awakenings</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.2 &#177; 1.1</td></tr><tr><td align="center" valign="middle" >Duration of morning stiffness</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Any</td><td align="center" valign="middle" >1 (5.9)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >&lt;15 min</td><td align="center" valign="middle" >6 (35.3)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >15 to 30 min</td><td align="center" valign="middle" >4 (23.5)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >30 min to 1 hour</td><td align="center" valign="middle" >3 (17.6)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >&gt;1 hour</td><td align="center" valign="middle" >3 (17.6)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Visual Analogue Scale</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >4.8 &#177; 1.3</td></tr><tr><td align="center" valign="middle" >DAS* 28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >]3.2 - 5.1]</td><td align="center" valign="middle" >3 (17.7)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >≥5.1</td><td align="center" valign="middle" >14 (82.4)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Accelerated ESR**</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >47.8 &#177; 24.6</td></tr><tr><td align="center" valign="middle" >Positive CRP***</td><td align="center" valign="middle" >12 (70.6)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Positive RF****</td><td align="center" valign="middle" >13 (76.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Positive anti-CCP*****</td><td align="center" valign="middle" >10 (58.8)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>*DAS 28: Disease Activity score 28; **ESR: Erythrocyte Sedimentation Rate; ***CRP: C reactive protein; ****RF: Rheumatoid factors; *****Anti CCP: Anti-cyclic citrullinated peptide antibody.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients with RA according to the electrocardiogram data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >No.</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Left atrial hypertrophy</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >29.4</td></tr><tr><td align="center" valign="middle" >Left ventricular hypertrophy</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11.8</td></tr><tr><td align="center" valign="middle" >Ventricular extrasystole</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11.8</td></tr><tr><td align="center" valign="middle" >QRS abnormalities</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >5.9</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution of RA patients according to cardiac Doppler data</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >No.</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >No abnormality</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >29.4</td></tr><tr><td align="center" valign="middle" >Left ventricular diastolic dysfunction</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >47.1</td></tr><tr><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >29.4</td></tr><tr><td align="center" valign="middle" >Moderate</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11.8</td></tr><tr><td align="center" valign="middle" >Very active</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >5.9</td></tr><tr><td align="center" valign="middle" >Pericardial effusion</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >11.8</td></tr><tr><td align="center" valign="middle" >Mitral valve leak</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >5.9</td></tr><tr><td align="center" valign="middle" >Tricuspid leak</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >5.9</td></tr></tbody></table></table-wrap><p>short study duration, small sample size, non-exhaustive biological investigations, reluctance of patients to undergo cardiological investigations and low socio-economic level. During the study period, the hospital incidence of RA was 5.9%. This frequency is lower than that reported in a previous Guinean study (7.9%) [<xref ref-type="bibr" rid="scirp.116709-ref13">13</xref>]. This may be due to the short duration of data collection. The mean age of patients was comparable to that found in Benin in 2015 (44 &#177; 10.6 years) [<xref ref-type="bibr" rid="scirp.116709-ref14">14</xref>]. This result could be explained by the fact that, according to the literature, RA most often affects women in the age group between 40 and 60 years [<xref ref-type="bibr" rid="scirp.116709-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref16">16</xref>]. Female predominance was also reported in African literature [<xref ref-type="bibr" rid="scirp.116709-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref19">19</xref>]. These results corroborated the female predominance described in the literature, suggesting the involvement of hormonal factors [<xref ref-type="bibr" rid="scirp.116709-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref21">21</xref>]. RA is a cardiovascular risk factor [<xref ref-type="bibr" rid="scirp.116709-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref24">24</xref>]. This risk is mainly related to the chronic inflammatory state that is caused by numerous metabolic changes [<xref ref-type="bibr" rid="scirp.116709-ref7">7</xref>]. The cardiovascular risk factors found in this series were similar to those found in France [<xref ref-type="bibr" rid="scirp.116709-ref25">25</xref>]. Some traditional cardiovascular risk factors in RA patients may contribute to the increased cardiovascular morbidity and mortality observed in RA [<xref ref-type="bibr" rid="scirp.116709-ref26">26</xref>]. A Senegalese study [<xref ref-type="bibr" rid="scirp.116709-ref27">27</xref>] and a Togolese study [<xref ref-type="bibr" rid="scirp.116709-ref19">19</xref>] reported a short average duration of RA. The long duration of progression of RA in this study is explained by the delay of consultation in specialised structures and the use of traditional medicine. Electrocardiogram abnormalities were less specific than those found in the study by Goulenok TM et al. [<xref ref-type="bibr" rid="scirp.116709-ref25">25</xref>]. The exclusion of patients with a history of cardiovascular disease could explain this result. The propensity for left ventricular diastolic dysfunction corroborated the data in the literature which describes it as the most common cardiac event in RA patients without clinically evident cardiac events. It is thought to be related to the duration of disease progression and activity of RA [<xref ref-type="bibr" rid="scirp.116709-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref29">29</xref>]. Valvulopathies (2 cases; 11.8%) were more commonly reported by Sarraj R et al. [<xref ref-type="bibr" rid="scirp.116709-ref18">18</xref>] (35 cases; 37.6%). The small sample size of our study may explain this difference in results. The rarity of rheumatoid pericarditis has been reported by Anastasio M [<xref ref-type="bibr" rid="scirp.116709-ref30">30</xref>] in relation to the asymptomatic nature of rheumatoid pericarditis (2% to 4%) [<xref ref-type="bibr" rid="scirp.116709-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.116709-ref27">27</xref>].</p></sec><sec id="s5"><title>5. Conclusion</title><p>In our study, we found asymptomatic cardiac manifestations of rheumatoid arthritis. They are of various kinds; highlighted by both electrocardiogram and cardiac echo-Doppler. This study, therefore, highlights the need for a systematic cardiac examination in patients with rheumatoid arthritis.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec id="s7"><title>Cite this paper</title><p>Kamissoko, A.B., Barry, I.S., Sanda, M., Houngbegnon, C.D., Diallo, M.L., Barry, A., Bald&#233;, M.D. and Oniankitan, O. (2022) Asymptomatic Cardiac Manifestations in Rheumatoid Arthritis in Conakry (Guinea). Open Journal of Rheumatology and Autoimmune Diseases, 12, 57-64. https://doi.org/10.4236/ojra.2022.122007</p></sec></body><back><ref-list><title>References</title><ref id="scirp.116709-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Silman, A.J. and Hochberg, M.C. (2001) Epidemiology of the Rheumatic Diseases. Oxford University Press, Oxford.</mixed-citation></ref><ref id="scirp.116709-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Roux, H. (2002) Polyarthrite Rhumato&amp;#239;de en Afrique Subsaharienne. Revue du Rhumatisme, 69, 797-800. https://doi.org/10.1016/S1169-8330(02)00387-3</mixed-citation></ref><ref id="scirp.116709-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mouanaa, H., Zour, S., Hachfi, H., Hammami, S., Jguirim, M., et al. (2018) L’évaluation des manifestations extra-articulaires est une étape importante dans la prise en charge globale de la polyarthrite rhumato&amp;#239;de. La Revue de Médecine Interne, 39, A161-A162. https://doi.org/10.1016/j.revmed.2018.03.107</mixed-citation></ref><ref id="scirp.116709-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ndongo, S., Pouye, A., Daher, A., Ndao, A.C., Milogo, A., Ka, M.M., et al. (2011) Les manifestations cardiaques asymptomatiques au cours de la polyarthrite rhumato&amp;#239;de (PR) en milieu sénégalais. La Revue de Médecine Interne, 32, S370.https://doi.org/10.1016/j.revmed.2011.10.136</mixed-citation></ref><ref id="scirp.116709-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Watson, D.J., Rhodes, T. and Guess, H.A. (2003) All-Cause Mortality and Vascular Events among Patients with Rheumatoid Arthritis, Osteoarthritis, or No Arthritis in the UK General Practice Research Database. The Journal of Rheumatology, 30, 1196-1202.</mixed-citation></ref><ref id="scirp.116709-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Navarro-Cano, G., Del Rincon, I., Pogosian, S., Roldan, J.F. and Escalante, A. (2003) Association of Mortality with Disease Severity in Rheumatoid Arthritis, Independent of Comorbidity. Arthritis &amp; Rheumatism, 48, 2425-2433. https://doi.org/10.1002/art.11127</mixed-citation></ref><ref id="scirp.116709-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Da&amp;#239;en, C.I. and Fesler, P. (2012) La polyarthrite rhumato&amp;#239;de: Une maladie cardiovasculaire? Annales de Cardiologie et d’Angéiologie, 61, 111-117.https://doi.org/10.1016/j.ancard.2011.07.008</mixed-citation></ref><ref id="scirp.116709-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Assous, N., Touzé, E., Meune, C., Kahan, A. and Allanore, Y. (2007) Morbimortalité cardiovasculaire au cours de la polyarthrite rhumato&amp;#239;de: Etude de cohorte hospitalière monocentrique fran&amp;#231;aise. Revue du Rhumatisme, 74, 72-78.https://doi.org/10.1016/j.rhum.2006.05.019</mixed-citation></ref><ref id="scirp.116709-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Dodo-Siddo, M.N., Diao, M., Ndiaye, M.B., Ndongo, S., Kane, A., Mbaye, A., et al. (2016) étude des paramètres échocardiographiques de la polyarthrite rhumato&amp;#239;de noire africaine asymptomatique au plan cardiovasculaire: Etude transversale de 73 cas sénégalais. Annales de Cardiologie et d’Angéiologie, 65, 71-76.https://doi.org/10.1016/j.ancard.2015.01.015</mixed-citation></ref><ref id="scirp.116709-ref10"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gourine</surname><given-names> M. </given-names></name>,<etal>et al</etal>. (<year>2020</year>)<article-title>Le risque cardiovasculaire au cours de la polyarthrite rhumato&amp;#239;de</article-title><source> Algerian Journal of Health Sciences</source><volume> 2</volume>,<fpage> 52</fpage>-<lpage>67</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.116709-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Meryem, M., Rostom, S., Bahiri, R., Boudali, A. and Hajjaj-Hassouni, N. (2011) Cortico&amp;#239;des et risque cardiovasculaire dans la polyarthrite rhumato&amp;#239;de. https://www.researchgate.net/publication/281641365</mixed-citation></ref><ref id="scirp.116709-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Hua, C. and Combe, B. (2017) Les nouveaux critères de classification acr/eular 2010 pour un diagnostic plus précoce de la polyarthrite rhumato&amp;#239;de. Revue du Rhumatisme Monographies, 84, 337-342. https://doi.org/10.1016/j.monrhu.2017.07.001</mixed-citation></ref><ref id="scirp.116709-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Van der Heijde, D.M.F.M., van’t Hof, M.A., van Riel, P.L.C.M., et al. (1990) Judging Disease Activity in Clinical Practice in Rheumatoid Arthritis: First Step Development of Disease Activity Score. Annals of the Rheumatic Diseases, 49, 916-920. https://doi.org/10.1136/ard.49.11.916</mixed-citation></ref><ref id="scirp.116709-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kamissoko, A.B., Diallo, M.L., Traoré, M., Diallo, A., Yombouno, E., Barry, A., Yombouno, E., Barry, A., Touré, M., Awada, M. and Oniankitan, O. (2018) Panorama des maladies rhumatismales à Conakry. European Scientific Journal, 14, 422-431. https://doi.org/10.19044/esj.2018.v14n24p422</mixed-citation></ref><ref id="scirp.116709-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zomalhèto, Z., Azombakin, S., Goussanou, Y. and Laleye, A. (2015) Profil biologique de la polyarthrite rhumato&amp;#239;de dans un pays à ressource limité: A propos de 31 patients. Journal de la Société de Biologie Clinique du Bénin, 22, 9-12.</mixed-citation></ref><ref id="scirp.116709-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sany, J. (2003) La polyarthrite rhumato&amp;#239;de de l’adulte—Conception actuelle. 2nd Edition, John Libbey Eurotext, Montrouge, 284.</mixed-citation></ref><ref id="scirp.116709-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Djaroud, Z., Elabed, F., Miri, F., Benlebna, F. and Boumediene, Z.B. (2014) Education thérapeutique dans la polyarthrite rhumato&amp;#239;de: Bénéfice algo-fonctionnel et psychologique. Revue du Rhumatisme, 81, 141.</mixed-citation></ref><ref id="scirp.116709-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Sarraj, R., Brahem, M., Ibn, H.A.H., Toul, I., Amani, B.S., Grassa, H., et al. (2021) Les manifestations extra articulaires de la polyarthrite rhumato&amp;#239;de: Fréquence et facteurs associés. Revue du Rhumatisme, 88, A246. https://doi.org/10.1016/j.rhum.2021.10.406</mixed-citation></ref><ref id="scirp.116709-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kakpovi, K., Houzou, P., Fianyo, E., Koulou, M., Kueviakoé, M.I., Padaro, E., et al. (2017) Profil de la polyarthrite rhumato&amp;#239;de en consultation rhumatologique à Lomé. European Scientific Journal, 13, 1857-7431. https://doi.org/10.19044/esj.2017.v13n27p251</mixed-citation></ref><ref id="scirp.116709-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ghozlani, I., Labrini, F., Ghazi, M., Kherrab, A., Moutaoukil, M., et al. (2017) La polyarthrite rhumato&amp;#239;de: Actualités physiopathologiques et implications thérapeutiques. Journal de biologie médicale, 6, 61-69.</mixed-citation></ref><ref id="scirp.116709-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Allanore, Y., Meune, C., Duboc, D., Weber, S. and Kahan, A. (2006) Fréquente dysfonction myocardique diastolique au cours de la polyarthrite rhumato&amp;#239;de. Revue du Rhumatisme, 73, 1065-1066. https://doi.org/10.1016/j.rhum.2006.10.102</mixed-citation></ref><ref id="scirp.116709-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Gabriel, S.E. (2010) Heart Disease and Rheumatoid Arthritis: Understanding the Risks. Annals of the Rheumatic Diseases, 69, 61-64. https://doi.org/10.1136/ard.2009.119404</mixed-citation></ref><ref id="scirp.116709-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Daldoun, C., El Amri, N., Laataoui, S., Baccouche, K., Zeglaoui, H. and Bouajina, E. (2021) Le DAS28 γGT: Un simple outil pour l’évaluation du risque cardiovasculaire et de l’activité de la polyarthrite rhumaoto&amp;#239;de. La Revue de Médecine Interne, 42, A187. https://doi.org/10.1016/j.revmed.2021.03.188</mixed-citation></ref><ref id="scirp.116709-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ghoslani, I. and El Maghraoui, A. (2015) Nouveaux facteurs risque cardiovasculaire dans la polyarthrite rhumato&amp;#239;de. Revue marocaine de rhumatologie, 33, 10-15.</mixed-citation></ref><ref id="scirp.116709-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Goulenok, T.M., Meune, C., Gossec, L., Dougados, M., Kahan, A. and Allanore, Y. (2010) Usefulness of Routine Electrocardiography for Heart Disease Screening in Patients with Spondyloarthropathy or Rheumatoid Arthritis. Joint Bone Spine, 77, 146-150. https://doi.org/10.1016/j.jbspin.2010.01.001</mixed-citation></ref><ref id="scirp.116709-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Boyer, J.F., Gourraud, P.A., Cantagrel, A., Davignon, J.L. and Constantin, A. (2011) Méta-analyse des facteurs de risque traditionnels dans la polyarthrite rhumato&amp;#239;de. Revue du Rhumatisme, 78, 245-250. https://doi.org/10.1016/j.rhum.2011.02.006</mixed-citation></ref><ref id="scirp.116709-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Dodo-Siddo, M.N., Sarr, S.A., Ndiaye, M., Bodian, M., Ndongo, S., et al. (2015) Importance of Electrocardiogram for Detection of Preclinical Abnormalities in Patients with Rheumatoid Arthritis without Cardiovascular Events. Journal of Arthritis, 4, Article No. 155.</mixed-citation></ref><ref id="scirp.116709-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Gonzalez-Juanatey, C., Testa, A., Garcia-Costelo, C., et al. (2004) Echocardiographic and Doppler Findings in Long-Term Treated Rheumatoid Arthritis Patients without Clinically Evident Cardiovascular Disease. Seminars in Arthritis and Rheumatism, 33, 231-238.</mixed-citation></ref><ref id="scirp.116709-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Masooleh, I.S., Zayeni, H., Haji-Abbasi, A., Azarpira, M., Hadian, A., Hassankhani, A. and Parsa, B.G. (2016) Cardiac Involvement in Rheumatoid Arthritis: A Cross-Sectional Study in Iran. Indian Heart Journal, 68, 332-335.https://doi.org/10.1016/j.ihj.2015.08.030</mixed-citation></ref><ref id="scirp.116709-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Anastasio, M., Lamy, O., Ribi, C., Zufferey, P., Gianinazzi, F. and Benmachiche, M. (2016) Quand un diagnostic peut cacher un autre. Forum Médical Suisse, 16, 744-747.</mixed-citation></ref></ref-list></back></article>